MSA SAFETY INC (MSA) Spending and interest coverage
- R&D / revenue · 12 months: Value 3.50%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.97%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 3.50% | Research and development expense / revenue. Period ending 2026-06-30. $68.19M ÷ $1.95B × 100 ≈ 3.50% |
| Stock-based compensation / revenue · 12 months | 0.97% | Share-based compensation / revenue. Period ending 2026-06-30. $18.82M ÷ $1.95B × 100 ≈ 0.97% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 68.19M USD | Research and Development Expense |
| Revenue | 1.95B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 18.82M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 413.17M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $68.19M | $1.95B | $18.82M | $413.17M | (m) | 3.50% | 0.97% | (m) | (m) |
| 2026-03-31 | $66.03M | $1.92B | $16.38M | $387.07M | (m) | 3.44% | 0.85% | (m) | (m) |
| 2025-12-31 | $65.34M | $1.87B | $15.20M | $371.82M | (m) | 3.49% | 0.81% | (m) | (m) |
| 2025-09-30 | $66.02M | $1.86B | $16.09M | $375.58M | (m) | 3.54% | 0.86% | (m) | (m) |
| 2025-06-30 | $66.20M | $1.83B | $16.95M | $372.74M | (m) | 3.62% | 0.93% | (m) | (m) |
| 2025-03-31 | $66.28M | $1.82B | $16.63M | $386.83M | (m) | 3.65% | 0.92% | (m) | (m) |
| 2024-12-31 | $66.53M | $1.81B | $18.18M | $389.18M | (m) | 3.68% | 1.01% | (m) | (m) |
| 2024-09-30 | $68.78M | $1.80B | $21.96M | $373.78M | (m) | 3.81% | 1.22% | (m) | (m) |
| 2024-06-30 | $69.75M | $1.82B | $26.22M | $376.43M | $42.48M | 3.84% | 1.44% | 8.86× | Reported |
| 2024-03-31 | $68.67M | $1.80B | $27.94M | $371.49M | $46.00M | 3.81% | 1.55% | 8.08× | Reported |
| 2023-12-31 | $67.99M | $1.79B | $30.02M | $231.32M | $46.73M | 3.80% | 1.68% | 4.95× | Reported |
| 2023-09-30 | $62.90M | $1.74B | $29.83M | $199.69M | $44.65M | 3.62% | 1.72% | 4.47× | Reported |
| 2023-06-30 | $59.63M | $1.67B | $24.32M | $169.88M | $38.12M | 3.57% | 1.46% | 4.46× | Reported |
| 2023-03-31 | $58.91M | $1.60B | $22.19M | $136.41M | $29.52M | 3.69% | 1.39% | 4.62× | Reported |
| 2022-12-31 | $57.01M | $1.53B | $19.65M | $239.14M | $21.66M | 3.73% | 1.29% | 11.04× | Reported |
| 2022-09-30 | $58.66M | $1.49B | $16.67M | $79.68M | $17.07M | 3.92% | 1.12% | 4.67× | Reported |
| 2022-06-30 | $59.19M | $1.45B | $16.57M | $47.77M | $14.87M | 4.07% | 1.14% | 3.21× | Reported |
| 2022-03-31 | $57.89M | $1.42B | $19.34M | $21.36M | $12.46M | 4.07% | 1.36% | 1.71× | Reported |
| 2021-12-31 | $57.79M | $1.40B | $18.91M | $22.78M | $10.76M | 4.13% | 1.35% | 2.12× | Reported |
| 2021-09-30 | $58.69M | $1.38B | $17.44M | $126.69M | $9.37M | 4.26% | 1.27% | 13.52× | Reported |
| 2021-06-30 | $57.60M | $1.34B | $13.26M | $138.86M | $7.91M | 4.29% | 0.99% | 17.55× | Reported |
| 2021-03-31 | $57.39M | $1.32B | $6.69M | $152.11M | $8.20M | 4.36% | 0.51% | 18.55× | Reported |
| 2020-12-31 | $58.27M | $1.35B | $6.92M | $166.85M | $9.43M | 4.32% | 0.51% | 17.69× | Reported |
| 2020-09-30 | $58.09M | $1.34B | $6.67M | $188.19M | $10.41M | 4.35% | 0.50% | 18.08× | Reported |
| 2020-06-30 | $57.76M | $1.38B | $12.03M | $206.67M | $12.36M | 4.18% | 0.87% | 16.72× | Reported |
| 2020-03-31 | $58.26M | $1.42B | $14.54M | $212.85M | $14.37M | 4.11% | 1.03% | 14.81× | Reported |
| 2019-12-31 | $57.85M | $1.40B | $13.76M | $186.23M | $13.59M | 4.13% | 0.98% | 13.70× | Reported |
| 2019-09-30 | $54.43M | $1.39B | $12.77M | $188.50M | $15.52M | 3.92% | 0.92% | 12.15× | Reported |
| 2019-06-30 | $54.20M | $1.37B | $10.63M | $168.88M | $15.75M | 3.96% | 0.78% | 10.72× | Reported |
| 2019-03-31 | $53.85M | $1.36B | $9.38M | $161.20M | $16.46M | 3.96% | 0.69% | 9.79× | Reported |
| 2018-12-31 | $52.70M | $1.36B | $12.24M | $173.48M | $18.88M | 3.88% | 0.90% | 9.19× | Reported |
| 2018-09-30 | $54.53M | $1.34B | $11.69M | $102.58M | $19.25M | 4.06% | 0.87% | 5.33× | Reported |
| 2018-06-30 | $53.59M | $1.31B | $11.22M | $102.46M | $18.72M | 4.10% | 0.86% | 5.47× | Reported |
| 2018-03-31 | $51.61M | $1.26B | $11.04M | $69.16M | $16.55M | 4.11% | 0.88% | 4.18× | Reported |
| 2017-12-31 | $50.06M | $1.20B | $11.76M | $43.34M | $15.36M | 4.18% | 0.98% | 2.82× | Reported |
| 2017-09-30 | $47.51M | $1.15B | $10.59M | $121.89M | $14.46M | 4.14% | 0.92% | 8.43× | Reported |
| 2017-06-30 | $48.27M | $1.13B | $10.49M | $121.29M | $14.91M | 4.28% | 0.93% | 8.13× | Reported |
| 2017-03-31 | $47.48M | (m) | $10.04M | $154.89M | $16.10M | (m) | (m) | 9.62× | Reported |
| 2016-12-31 | $46.85M | $1.15B | $9.21M | $164.19M | $16.41M | 4.08% | 0.80% | 10.00× | Reported |
| 2016-09-30 | $46.82M | (m) | $8.96M | (m) | $15.57M | (m) | (m) | (m) | Reported |
| 2016-06-30 | $46.24M | (m) | $7.76M | (m) | $13.98M | (m) | (m) | (m) | Reported |
| 2016-03-31 | $48.08M | (m) | $8.12M | (m) | $12.28M | (m) | (m) | (m) | Reported |
| 2015-12-31 | $48.63M | (m) | $7.60M | (m) | $10.85M | (m) | (m) | (m) | Reported |
| 2015-09-30 | $48.07M | (m) | $8.10M | (m) | $10.04M | (m) | (m) | (m) | Reported |
| 2015-06-30 | $48.96M | (m) | $9.03M | (m) | $9.70M | (m) | (m) | (m) | Reported |
| 2015-03-31 | $47.92M | (m) | $8.87M | (m) | $9.79M | (m) | (m) | (m) | Reported |
| 2014-12-31 | $48.25M | (m) | $9.05M | (m) | $9.85M | (m) | (m) | (m) | Reported |
| 2014-09-30 | $48.18M | (m) | $9.08M | (m) | $10.14M | (m) | (m) | (m) | Reported |
| 2014-06-30 | $47.06M | (m) | $9.20M | (m) | $10.39M | (m) | (m) | (m) | Reported |
| 2014-03-31 | $46.52M | (m) | $10.31M | (m) | $10.55M | (m) | (m) | (m) | Reported |
| 2013-12-31 | $45.86M | (m) | $10.34M | (m) | $10.68M | (m) | (m) | (m) | Reported |
| 2013-09-30 | $45.47M | (m) | $12.26M | (m) | $10.65M | (m) | (m) | (m) | Reported |
| 2013-06-30 | $43.25M | (m) | $12.66M | (m) | $10.71M | (m) | (m) | (m) | Reported |
| 2013-03-31 | $42.19M | (m) | $12.29M | (m) | $10.87M | (m) | (m) | (m) | Reported |
| 2012-12-31 | $40.90M | (m) | $10.01M | (m) | $11.36M | (m) | (m) | (m) | Reported |
| 2012-09-30 | $39.31M | (m) | $8.37M | (m) | $12.55M | (m) | (m) | (m) | Reported |
| 2012-06-30 | $38.90M | (m) | $8.38M | (m) | $12.96M | (m) | (m) | (m) | Reported |
| 2012-03-31 | $37.99M | (m) | $7.96M | (m) | $13.83M | (m) | (m) | (m) | Reported |
| 2011-12-31 | $39.24M | (m) | $7.73M | (m) | $14.12M | (m) | (m) | (m) | Reported |
| 2011-09-30 | $38.47M | (m) | $7.72M | (m) | $14.22M | (m) | (m) | (m) | Reported |
| 2011-06-30 | $36.75M | (m) | $7.57M | (m) | $12.71M | (m) | (m) | (m) | Reported |
| 2011-03-31 | $35.59M | (m) | $7.52M | (m) | $10.60M | (m) | (m) | (m) | Reported |
| 2010-12-31 | $32.78M | (m) | $7.33M | (m) | $8.71M | (m) | (m) | (m) | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $28.78M | (m) | $5.86M | (m) | $7.08M | (m) | (m) | (m) | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $35.02M | (m) | $5.46M | (m) | $8.92M | (m) | (m) | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B | |
| NutriBand Inc. (NTRB) | United States | $0.109B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |